A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties
Jie Zhao, Liangfeng Jiang, Haodong Yang, Lan Deng, Xiaoqing Meng, Jian Ding, Sixing Yang, Le Zhao, Wei Xu, Xiaolong Wang, Zhenping Zhu, Haomin Huang
Abstract
format, we successfully produced a series of tetravalent IgG-like BsAbs that simultaneously target PD1 and other immune checkpoint targets, including PDL1 and CTLA4. The BsAbs exhibited superior bioactivities in vitro and in vivo compared to their respective parental mAbs. Importantly, the BsAbs demonstrated the desired IgG-like physicochemical properties in terms of high-level expression, ease of purification to homogeneity, good stability and in vivo pharmacokinetics. In summary, we describe a novel and flexible plug-and-play platform to engineer IgG-like BsAbs with excellent development potential for clinical applications.